Show simple item record

dc.contributor.authorHulmi, Juha J.
dc.contributor.authorNissinen, Tuuli A.
dc.contributor.authorPenna, Fabio
dc.contributor.authorBonetto, Andrea
dc.date.accessioned2021-03-15T12:22:36Z
dc.date.available2021-03-15T12:22:36Z
dc.date.issued2021
dc.identifier.citationHulmi, J. J., Nissinen, T. A., Penna, F., & Bonetto, A. (2021). Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments. <i>Cells</i>, <i>10</i>(3), Article 516. <a href="https://doi.org/10.3390/cells10030516" target="_blank">https://doi.org/10.3390/cells10030516</a>
dc.identifier.otherCONVID_51896265
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/74634
dc.description.abstractMuscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and increased morbidity and mortality. Anticancer treatments have also been shown to contribute to sustainment or exacerbation of cachexia, thus affecting quality of life and overall survival in cancer patients. Pre-clinical studies have shown that blocking activin receptor type 2 (ACVR2) or its ligands and their downstream signaling can preserve muscle mass in rodents bearing experimental cancers, as well as in chemotherapy-treated animals. In tumor-bearing mice, the prevention of skeletal and respiratory muscle wasting was also associated with improved survival. However, the definitive proof that improved survival directly results from muscle preservation following blockade of ACVR2 signaling is still lacking, especially considering that concurrent beneficial effects in organs other than skeletal muscle have also been described in the presence of cancer or following chemotherapy treatments paired with counteraction of ACVR2 signaling. Hence, here, we aim to provide an up-to-date literature review on the multifaceted anti-cachectic effects of ACVR2 blockade in preclinical models of cancer, as well as in combination with anticancer treatments.en
dc.format.mimetypeapplication/pdf
dc.languageeng
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCells
dc.rightsCC BY 4.0
dc.subject.othercancer cachexia
dc.subject.othertumor
dc.subject.otherchemotherapy
dc.subject.othermyostatin
dc.subject.otheractivins
dc.subject.othermuscle wasting
dc.subject.othersurvival
dc.subject.othermortality
dc.subject.othermulti-organ
dc.titleTargeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202103151975
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineLiikuntafysiologiafi
dc.contributor.oppiaineExercise Physiologyen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.description.reviewstatuspeerReviewed
dc.relation.issn2073-4409
dc.relation.numberinseries3
dc.relation.volume10
dc.type.versionpublishedVersion
dc.rights.copyright© 2021 the Authors
dc.rights.accesslevelopenAccessfi
dc.relation.grantnumber275922
dc.subject.ysolihassurkastumasairaudet
dc.subject.ysosoluviestintä
dc.subject.ysoproteiinit
dc.subject.ysosyöpähoidot
dc.subject.ysohenkiinjääminen
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p15977
jyx.subject.urihttp://www.yso.fi/onto/yso/p28740
jyx.subject.urihttp://www.yso.fi/onto/yso/p4332
jyx.subject.urihttp://www.yso.fi/onto/yso/p27422
jyx.subject.urihttp://www.yso.fi/onto/yso/p14692
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.3390/cells10030516
dc.relation.funderSuomen Akatemiafi
dc.relation.funderAcademy of Finlanden
jyx.fundingprogramAkatemiatutkija, SAfi
jyx.fundingprogramAcademy Research Fellow, AoFen
jyx.fundinginformationThis review received no external funding but was supported by the Faculty of Sport and Health Sciences at University of Jyväskylä, the Department of Clinical and Biological Sciences at University of Turin and the Department of Surgery at Indiana University. The research leading to the results presented here also received funding from the Academy of Finland (grant No. 275922 to J.J.H.), Cancer Society of Finland (to J.J.H.), Jenny and Antti Wihuri as well as Ellen and Artturi Nyyssönen Foundations (to T.A.N.), AIRC (under IG 2018-ID. 21963 project to F.P.) and American Cancer Society (Research Scholar Grant 132013-RSG-18-010-01-CCG to A.B.).


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0